Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses

NCT04380779 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2430

Last updated 2020-12-14

No results posted yet for this study

Summary

The main objectives are:

* To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses.
* To identify variables associated to higher risk of bleeding.

Conditions

Sponsors & Collaborators

  • Manuel Monreal

    lead OTHER

Principal Investigators

  • Manuel Monreal · Germans Trias i Pujol Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-13
Primary Completion
2020-10-13
Completion
2020-10-13

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04380779 on ClinicalTrials.gov